Case report and review of a novel chromosomal abnormality in AML patient

SAN DIEGO — More than 70% of patients with heavily pretreated multiple myeloma responded to an investigational bispecific antibody targeting B-cell maturation antigen (BCMA) and

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics ap­pears to be a weak­er pso­ri­a­sis treat­ment than some of its in­jectable com­pe­ti­tion, ac­cord­ing